Tamara J. Laskowski, Phd Email & Phone Number

Houston, TX, US

Basel, CH

• As a global leadership team member, I manage scientific and clinical partnerships with key opinion leaders/principal investigators in the fields of precision medicine and clinical oncology to advance next-generation.
• Develop/nurture key partnerships and collaborations with external parties within the broader scientific community
• Contribute to business strategy decisions to support commercial development;
• Lead a team of 10 scientists; Provide scientific technical leadership for cell therapy-based immuno-oncology programs from pre-clinical development to first-in-human studies;
• Partner with investigators to develop processes that will meet their clinical needs and address scalability and COGS reduction; Define scope of development projects, including cost estimates and timelines; Review.
• Enhance cell processing and manufacturing activities through adoption and implementation of innovative technologies to expand upstream and downstream process capabilities; Identify opportunities for process.

Houston, TX, US

Under the leadership of Dr. Katy Rezvani, the Adoptive Cell Therapy (ACT) platform is an academia-industry hybrid sector dedicated to the development of innovative off-the-shelf cellular immunotherapies to treat hematological and solid malignancies. Our goal is to augment the power of NK and T-cells through customized genetic engineering and thus confer to.

Houston, TX, US

Under the leadership of Dr. James Allison and Dr. Padmanee Sharma, the Immunotherapy Platform-deployed COVID-19 task force focuses on deciphering the immune mechanisms associated with response to COVID-19 in cancer patients.As part of the team, I served as lead scientist responsible for the development of CyTOF and cytokine profiling platforms to.

Houston, TX, US

Led by Nobel laureate Dr. James Allison, the Immunotherapy platform is a multi-disciplinary team structure blending together academia and industry, with focus on uncovering the challenges that impair immune function in the tumor microenvironment and devising ways to empower the immune system to overcome these challenges. In my role as a Senior Scientist I.

Houston, TX, US

Under the mentorship of Dr. Laurence J.N. Cooper, MD, PhD, worked on developing iPSC platforms for generation of off-the-shelf CAR T-cells and CAR-NK cells for targeting solid and hematological malignancies. Developed genetically-modified iPSC lines for generation of multi-edited T and NK cell products; Generated and validated iPS cell banks; Focused on.

Instruct physicians, scientists, and trainees on how to communicate science to business professionals and to the lay public. Focus on the principles of effective and audience-tailored speeches through complete and concise scientific communication. Train professionals on how to build an impactful elevator pitch that enthusiastically communicates the value.

Support the career of women scientists in the STEM fields through workshops, seminars, and mentoring. Increase the presence and impact of AWIS GCH in the scientific community of the greater Houston-Gulf Coast area.

National Science Foundation program for innovation and entrepreneurship with focus on training a select group of scientists on how to assess the requirements for commercialization of their discoveries.Program description (https://www.nsf.gov/news/special_reports/i-corps/): The National Science Foundation (NSF) I-Corps program prepares scientists and.

Doctor Of Philosophy (Ph.D.), Human Molecular Genetics And Immunology

Bachelor'S Of Science, Biology Premedicine